8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2010

 

 

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   033-20897-D   91-2099117

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

22118 20th Avenue S.E., Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2010 Annual Meeting of the Stockholders of Helix BioMedix, Inc. (the “Company”) was held on May 13, 2010, at which the following matters were approved as follows:

 

  1. The election of the following three Class I directors to serve until the 2013 Annual Meeting of Stockholders or until such directors’ successors are elected and qualified:

 

Nominee

    For    Withheld    Broker Non-Votes

Randall L-W. Caudill

    13,229,594    150,566    5,647,185

Richard M. Cohen

    13,229,594    150,566    5,647,185

Barry L. Seidman

    13,167,878    212,282    5,647,185

 

  2. The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

19,004,251

   12,252   10,842   0

These are the final voting results.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HELIX BIOMEDIX, INC.
Dated: May 17, 2010   By:  

/s/    R. STEPHEN BEATTY        

    R. Stephen Beatty
    President and Chief Executive Officer

 

3